Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.9
Journals
JCM
Special Issues
Recent Advances in Transcatheter Aortic Valve Replacement: Second Edition
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Recent Advances in Transcatheter Aortic Valve Replacement: Second Edition

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiovascular Medicine".

Deadline for manuscript submissions: 18 December 2025 | Viewed by 1716

Special Issue Editors

Dr. Anna Olasińska-Wiśniewska

E-Mail Website
Guest Editor
Department of Cardiac Surgery and Transplantology, Poznan University of Medical Sciences, 61-848 Poznan, Poland
Interests: aortic stenosis; TAVI; heart failure; coronary artery disease; atrial fibrillation
Special Issues, Collections and Topics in MDPI journals
Dr. Maciej Dąbrowski

E-Mail
Guest Editor
Department of Interventional Cardiology and Angiology, National Institute of Cardiology, Warsaw, Poland
Interests: coronary angioplasty; aortic stenosis; transcatheter aortic valve implantation; hypertrophic cardiomyopathy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

It is our pleasure to invite you to contribute to this Special Issue entitled “Recent Advances in Transcatheter Aortic Valve Replacement: Second Edition”. This is a new Special Issue that proceeds from the six papers we published in the first edition. For more details, you can access it here: https://www.mdpi.com/journal/jcm/special_issues/C7511T6741.

Transcatheter aortic valve replacement (TAVI) has evolved rapidly since the first procedure in 2002. Currently, TAVI is the recommended method of treatment for patients with severe aortic stenosis with moderate-to-high surgical risk, in addition to some selected low-risk patients. Diagnostic modalities support the proper qualification for this procedure. Modifications of the technique, bioprostheses, and delivery systems enable operators to perform the procedure relatively safely, even in particularly difficult clinical scenarios. Nevertheless, several troublesome issues may occur during or after the procedure. The aim of this Special Issue is to share experiences in pre-procedural planning, procedural techniques, and post-procedural outcomes in order to broaden the knowledge on TAVI performance and improve TAVI team skills.

We invite authors to share their valuable opinions and the results of their research as original or review papers. We would be very grateful for your outstanding contribution to the further development of TAVI.

Dr. Anna Olasinska-Wisniewska
Dr. Maciej Dąbrowski
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • aortic stenosis
  • transcatheter
  • bioprosthesis
  • TAVI
  • transcatheter aortic valve replacement

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

21 pages, 2629 KB  
Article
Three-Year Follow-Up of the First 100 Patients Treated with the Balloon-Expandable Myval Transcatheter Aortic Valve System: A Single-Centre Experience
by Balázs Magyari, Bálint Kittka, Ilona Goják, Gábor Kasza, Kristóf Schönfeld, László Botond Szapáry, Mihály Simon, Rudolf Kiss, Andrea Bertalan, Edit Várady, Péter Mátrai, István Szokodi and Iván Horváth
J. Clin. Med. 2025, 14(21), 7883; https://doi.org/10.3390/jcm14217883 - 6 Nov 2025
Viewed by 446
Abstract
Background/Objectives: To report our single-centre experience with the first 100 patients who underwent transcatheter aortic valve replacement (TAVR) with the new balloon-expandable Myval system. We report 3-year outcomes in low- to high-risk TAVR patient populations. Methods: From November 2019 to July 2021, 100 [...] Read more.
Background/Objectives: To report our single-centre experience with the first 100 patients who underwent transcatheter aortic valve replacement (TAVR) with the new balloon-expandable Myval system. We report 3-year outcomes in low- to high-risk TAVR patient populations. Methods: From November 2019 to July 2021, 100 consecutive patients underwent TAVR, and their outcomes were classified according to the Valve Academic Research Consortium 3 definitions. Device performance was assessed using transthoracic echocardiography. Data collection was approved by the local ethical committee. Results: Among the 100 patients, most were male (n = 63), the mean age was 74.7 years, the mean EuroSCORE II score was 4.8 ± 4.9, and the mean Society of Thoracic Surgeons score was 5.6 ± 3.9. All patients were followed up for three years or until death. The rates of all-cause mortality, cardiac mortality and stroke were 28%, 7% and 5%, respectively. After three years, residual moderate aortic regurgitation was detected in eight patients without severe grade, and bioprosthetic valve dysfunction was observed in 17: structural valve deterioration in 10 (only stage 2), non-structural valve deterioration in three (paravalvular leak in one, patient–prosthesis mismatch in two), and endocarditis in four. Definite transcatheter heart valve thrombosis (hypoattenuated leaflet thickening) was not observed. Bioprosthetic valve failure was detected in four patients (stage 1: 1, stage 2: 0, stage 3: 3). After three years of follow-up, survival analysis revealed no significant differences in all-cause mortality, cardiac mortality, or the composite endpoint (including cardiac mortality, stroke and valve-related dysfunction) between patients with bicuspid (BAV) and tricuspid (TAV) aortic valve morphology and across annulus sizes (small, intermediate and large). Conclusions: TAVR resulted in significant and sustained improvements in valve haemodynamics with low rates of valve dysfunction and adverse clinical outcomes over a three-year follow-up period. Valve morphology (BAV vs. TAV) and annulus size did not significantly impact survival, haemodynamic performance, or valve durability. These results support the expanded use of TAVR in diverse patient populations, although extended follow-up is essential to fully establish long-term durability. Full article
(This article belongs to the Special Issue Recent Advances in Transcatheter Aortic Valve Replacement: Second Edition)
►▼ Show Figures

Figure 1

Review

Jump to: Research

16 pages, 1803 KB  
Review
Valve-in-Valve Transcatheter Aortic Valve Implantation Versus Redo SAVR for Degenerated Biological Prosthesis: A Narrative Review Stating Our Experience
by Salvatore Torre, Laura Asta, Adriana Sbrigata, Sebastiano Castrovinci, Enrico Amoncelli, Antonio Segreto, Giuseppe Maria Raffa, Gioachino Agostino Giarratana, Vincenzo Argano and Calogera Pisano
J. Clin. Med. 2025, 14(20), 7158; https://doi.org/10.3390/jcm14207158 - 11 Oct 2025
Viewed by 881
Abstract
Surgical aortic valve replacement (SAVR) is still the gold-standard treatment for aortic stenosis. However, the increasing use of biological prostheses, even in young patients, makes Valve-in-Valve (ViV) transcatheter aortic valve implantation (TAVI) an attractive option compared to redo SAVR, thanks to its lower [...] Read more.
Surgical aortic valve replacement (SAVR) is still the gold-standard treatment for aortic stenosis. However, the increasing use of biological prostheses, even in young patients, makes Valve-in-Valve (ViV) transcatheter aortic valve implantation (TAVI) an attractive option compared to redo SAVR, thanks to its lower invasiveness and sometimes greater safety. However, there are several technical and anatomical aspects to consider. Therefore, the aim of our review is to examine the main mechanisms responsible for the degeneration of biological prostheses and, subsequently, to analyze the hemodynamic (transvalvular gradients, patient–prosthesis mismatch, paravalvular leakage) and technical (risk of coronary obstruction, prosthetic implantation strategy) aspects that most influence the procedure’s success and long-term outcomes. To this end, we present a case we treated in order to enhance our readers’ experience with this procedure. Currently, ViV TAVI is approved for patients at high surgical risk, but it could become a valid option compared to redo SAVR; however, more clinical trials are needed to better analyze the survival differences between these two procedures. Furthermore, it remains a therapeutic strategy reserved for highly specialized centers due to the technical difficulties involved in its execution. Full article
(This article belongs to the Special Issue Recent Advances in Transcatheter Aortic Valve Replacement: Second Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop